share_log

Insider Buying: Eterna Therapeutics Inc. (NASDAQ:ERNA) Major Shareholder Buys $1,101,817.60 in Stock

Insider Buying: Eterna Therapeutics Inc. (NASDAQ:ERNA) Major Shareholder Buys $1,101,817.60 in Stock

內幕購買:埃特納治療股份有限公司(NASDAQ:ERNA)主要股東購買 1,101,817.60 美元的股票
Financial News Live ·  2022/12/08 05:11

Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating) major shareholder John D. Halpern acquired 335,920 shares of the stock in a transaction on Friday, December 2nd. The stock was acquired at an average cost of $3.28 per share, for a total transaction of $1,101,817.60. Following the acquisition, the insider now directly owns 450,961 shares in the company, valued at approximately $1,479,152.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.

埃特娜治療公司(NASDAQ:ERNA-獲得評級)主要股東約翰·哈爾彭於 12 月 2 日(星期五)在一項交易中收購了該股 335,920 股股份。該股票以每股 3.28 美元的平均成本收購,總交易額為 1,101,817.60 美元。收購後,內幕人士目前直接擁有該公司 450,961 股股份,價值約為 1,479,152.08 美元。該收購已在向證券交易委員會提交的文件中披露,可以通過以下方式訪問 證券交易所網站。擁有至少 10% 的公司股份的主要股東必須向 SEC 披露其銷售和購買情況。

Eterna Therapeutics Trading Up 4.7 %

治療學交易上升 4.7%

Shares of NASDAQ:ERNA opened at $4.67 on Thursday. Eterna Therapeutics Inc. has a 12 month low of $2.73 and a 12 month high of $127.60.

納斯達克:埃爾納的股票在周四開盤 4.67 美元。埃特納治療公司擁有 12 個月低點 2.73 美元,12 個月高點為 127.60 美元。

Get
取得
Eterna Therapeutics
治疗
alerts:
警報:

About Eterna Therapeutics

關於埃特納治療

(Get Rating)

(取得評分)

Brooklyn ImmunoTherapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
布魯克林免疫治療有限公司是臨床階段生物製藥公司,致力於開發治療癌症患者的療法。其先進的計劃是 IRX-2,在頭部和頸部鱗狀細胞癌患者中處於 2b 期臨床試驗中。該公司還開發了使用基因編輯和細胞治療技術的治療腫瘤,血液疾病和單原性疾病的治療方法。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
  • Are Investors Hearing The End Of Spotify's Downtrend?
  • The Question of a Fed Pivot Isn't If, It's When, Here's Why
  • Top 10 Searched Stocks on MarketBeat All-Access
  • 3 Dividend Kings With Royally Good Upside
  • Institutions Sell The Rallies In Toll Brothers Stock
  • 獲取有關埃特納治療學(ERNA)的研究報告的免費副本
  • 投資者是否聽到 Spotify 下降趨勢的結束?
  • 美聯儲樞軸的問題不是如果,這是什麼時候,這就是為什麼
  • 全方位市場上十大搜索股票
  • 3 股息國王與皇家良好的上升
  • 機構出售收費兄弟股票的集會

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Eterna 治療日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Eterna 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論